1048960-67-3Relevant academic research and scientific papers
Development of orally bioavailable and CNS penetrant biphenylaminocyclopropane carboxamide bradykinin B1 receptor antagonists
Kuduk, Scott D.,Di Marco, Christina N.,Chang, Ronald K.,Wood, Michael R.,Schirripa, Kathy M.,Kim, June J.,Wai, Jenny M. C.,DiPardo, Robert M.,Murphy, Kathy L.,Ransom, Richard W.,Harrell, C. Meacham,Reiss, Duane R.,Holahan, Marie A.,Cook, Jacquelynn,Hess, J. Fred,Sain, Nova,Urban, Mark O.,Tang, Cuyue,Prueksaritanont, Thomayant,Pettibone, Douglas J.,Bock, Mark G.
, p. 272 - 282 (2007/10/03)
A series of biphenylaminocyclopropane carboxamide based bradykinin B 1 receptor antagonists has been developed that possesses good pharmacokinetic properties and is CNS penetrant. Discovery that the replacement of the trifluoropropionamide in t
N-biphenyl(substituted methyl) aminocycloalkane-carboxamide derivatives
-
, (2008/06/13)
N-Biphenyl(substituted methyl)aminocycloalkanecarboxamide derivatives are bradykinin B1 antagonists or inverse agonists useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway.
